Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer.
This review will analyze the current evidence supporting established predictive biomarkers, including PD-L1 expression, while highlighting their major limitations, and discuss and summarize emerging clinical and molecular biomarkers and integrative predictive approaches aimed at improving the stratification of patients...